IMMX

+ Watchlist + Portfolio

Immix Biopharma, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.23
52-Week Range: $2.00 – $15.10
Market Cap: $802.50M
P/E (TTM): —
EPS (TTM): -0.88
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.02
PEG Ratio: —
Return on Equity: -34.18%
Return on Assets: -20.52%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 25.13
Debt/Equity: 0.00
Total Debt: $1.00M
Free Cash Flow: $-25.39M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $461.40M

IMMX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$4.20M	$8.74M	$11.29M	$16.26M
Selling, General & Admin	$4.02M	$7.41M	$11.38M	$13.70M
Operating Expenses	$8.22M	$16.14M	$22.67M	$29.96M
Operating Income	-$8.22M	-$16.14M	-$22.67M	-$29.96M
EBITDA	-$8.22M	-$16.14M	-$22.56M	-$29.59M
Pretax Income	-$8.22M	-$15.57M	-$21.66M	-$29.40M
Income Tax	$10.27K	$26.41K	$41.04K	$37.72K
Net Income	-$8.23M	-$15.43M	-$21.61M	-$29.44M
Diluted EPS	-0.59	-0.89	-0.76	-0.89
Diluted Shares	13.89M	17.34M	28.29M	32.97M

IMMX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$13.44M	$17.51M	$17.68M	$93.93M
Receivables	$255.71K	$1.17M	$1.97M	$0.00
Current Assets	$14.90M	$19.79M	$20.20M	$101.24M
Total Assets	$14.91M	$19.93M	$22.95M	$104.84M
Current Liabilities	$1.27M	$3.72M	$8.69M	$10.11M
Total Debt	—	$0.00	$1.07M	$1.07M
Total Liabilities	$1.75M	$3.72M	$9.70M	$11.04M
Retained Earnings	-$37.99M	-$53.41M	-$75.02M	-$104.46M
Shareholders' Equity	$13.16M	$16.41M	$13.25M	$93.80M
Working Capital	$13.62M	$16.07M	$11.51M	$91.13M

IMMX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.41M	-$11.37M	-$14.60M	-$23.93M
Capital Expenditure	—	-$52.09K	-$1.18M	-$732.92K
Free Cash Flow	-$7.41M	-$11.42M	-$15.77M	-$24.66M
Depreciation & Amortisation	$2.13K	$5.47K	$115.39K	$364.50K
Stock-Based Compensation	$624.07K	$2.57M	$3.02M	$2.44M
Investing Cash Flow	$0.00	-$52.09K	-$1.18M	-$7.21M
Financing Cash Flow	$3.23M	$15.46M	$15.95M	$107.39M
Share Repurchases	-$99.96K	$0.00	—	—
Net Change in Cash	-$4.18M	$4.04M	$175.78K	$76.24M

IMMX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.98M	$3.97M	$4.58M	$5.73M	$5.98M	$5.33M
Selling, General & Admin	$2.71M	$2.75M	$3.08M	$5.17M	$4.82M	$7.12M
Operating Expenses	$4.68M	$6.72M	$7.66M	$10.89M	$10.80M	$12.46M
Operating Income	-$4.68M	-$6.72M	-$7.66M	-$10.89M	-$10.80M	-$12.46M
EBITDA	-$4.62M	-$6.64M	-$7.53M	-$10.80M	-$10.67M	-$12.33M
Pretax Income	-$4.53M	-$6.61M	-$7.58M	-$10.68M	-$10.09M	-$11.54M
Income Tax	$9.82K	$8.91K	$7.72K	$11.27K	$0.00	$14.32K
Net Income	-$4.54M	-$6.62M	-$7.59M	-$10.69M	-$10.09M	-$11.56M
Diluted EPS	-0.15	-0.22	-0.24	—	-0.18	-0.18
Diluted Shares	29.70M	29.98M	31.93M	—	55.37M	63.77M

IMMX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$15.92M	$11.64M	$15.95M	$93.93M	$79.25M	$225.49M
Receivables	$0.00	$0.00	$0.00	$0.00	—	—
Current Assets	$16.78M	$12.33M	$16.58M	$101.24M	$92.27M	$233.79M
Total Assets	$19.89M	$15.64M	$20.08M	$104.84M	$95.82M	$239.11M
Current Liabilities	$9.31M	$10.01M	$10.85M	$10.11M	$10.54M	$9.30M
Total Debt	$1.06M	$1.04M	$1.11M	$1.07M	$1.04M	$1.00M
Total Liabilities	$10.30M	$10.98M	$11.82M	$11.04M	$11.45M	$10.19M
Retained Earnings	-$79.57M	-$86.19M	-$93.78M	-$104.46M	-$114.55M	-$126.11M
Shareholders' Equity	$9.59M	$4.65M	$8.26M	$93.80M	$84.36M	$228.92M
Working Capital	$7.47M	$2.32M	$5.73M	$91.13M	$81.74M	$224.49M

IMMX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.69M	-$5.31M	-$5.91M	-$11.03M	-$9.83M	-$11.74M
Capital Expenditure	-$67.71K	-$127.63K	-$372.46K	-$165.13K	-$32.49K	-$21.04K
Free Cash Flow	-$1.75M	-$5.44M	-$6.28M	-$11.19M	-$9.86M	-$11.76M
Depreciation & Amortisation	$59.18K	$79.83K	$134.85K	$90.63K	$130.77K	$130.88K
Stock-Based Compensation	$868.36K	$532.25K	$470.47K	$570.80K	$575.57K	$978.14K
Investing Cash Flow	-$67.71K	-$127.63K	-$372.46K	-$6.65M	-$4.80M	$2.67M
Financing Cash Flow	$0.00	$1.11M	$10.61M	$95.67M	-$37.56K	$155.28M
Net Change in Cash	-$1.75M	-$4.33M	$4.33M	$77.99M	-$14.67M	$146.22M

Market Snapshot

About

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing oncology therapies targeting tissue factor and tissue factor pathway inhibitor (TFPI). The company's lead program focuses on treating solid tumors and hematological malignancies through novel mechanisms of action. Immix is advancing multiple candidates through preclinical and clinical development stages. The company's approach aims to address cancers with significant unmet medical needs through innovative targeting of the tissue factor pathway.